United Kingdom



BRIEF-Morphosys reports positive results from psoriasis study

* Morphosys announces that its licensee Janssen reports positive results from a phase 3 study of Guselkumab in plaque psoriasis Source text for Eikon: Further company coverage: (Reporting By Georgina Prodhan)

10:50am BST

J&J psoriasis drug tops placebo, Humira in late stage study

Oct 1 An experimental biotech drug developed by Johnson & Johnson proved more effective at clearing moderate to severe cases of the skin condition plaque psoriasis than a placebo or Abbvie Inc's big-selling Humira, according to data from a late stage study presented on Saturday.

7:00am BST

Regeneron eczema drug reduces itch and anxiety, two studies show

Oct 1 Patients taking an experimental eczema drug from Regeneron Pharmaceuticals Inc and Sanofi Inc experienced significant relief in itching and in anxiety and depression symptoms, meeting secondary goals of two large studies, researchers said on Saturday.

7:00am BST

Novartis psoriasis drug maintains efficacy after 4 years - study

ZURICH, Oct 1 Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson .

6:15am BST

BRIEF-Veracyte releases statement on CMS's final 2017 gapfill rate for afirma gene expression classifier

* Veracyte releases statement on cms's final 2017 gapfill rate for afirma gene expression classifier

1:09am BST
GlaxoSmithKline PLC 1,643.00p -0.27%
AstraZeneca PLC 5,004.00p -0.44%
Shire PLC 4,998.00p -1.25%


  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.